Fondazione IRCCS Istituto Nazionale dei Tumori-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2006

  1. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

    Bone Marrow Transplantation, Vol. 37, Núm. 12, pp. 1135-1141